SCHEMBL9965880

SCHEMBL9965880

Cn1nnc(C2[C@H]3CN(C(=O)OC(C)(C)C)C[C@@H]23)n1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.40
HTT P42858 1/20 0.38
ATM Q13315 1/20 0.38
ADRB3 P13945 1/20 0.38
KCNH2 Q12809 1/20 0.38
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
RORC P51449 1/20 0.36
SSTR4 P31391 1/20 0.35
JAK3 P52333 1/20 0.35
USP2 O75604 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GPR119 Q8TDV5 1/20 0.34
NAMPT P43490 1/20 0.34
USP30 Q70CQ3 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10189680 1.00 NR1H2 (0.40) NR1H2HTTATMADRB3KCNH2
SCHEMBL9963074 1.00 NR1H2 (0.40) NR1H2HTTATMADRB3KCNH2
SCHEMBL16182195 1.00 NR1H2 (0.40) NR1H2HTTATMADRB3KCNH2
SCHEMBL13216245 0.86 NR1H2 (0.41) NR1H2HTTATMDDB1CRBN
SCHEMBL9932445 0.80 ADRB3 (0.44) ADRB3KCNH2SMN1; SMN2
SCHEMBL2390750 0.79 MAPT (0.43) JAK3SMN1; SMN2GPR119USP30
SCHEMBL2390005 0.79 MAPT (0.43) JAK3SMN1; SMN2GPR119USP30
SCHEMBL3588386 0.78 THRB (0.48) HTTJAK3SMN1; SMN2GPR119NAMPT
SCHEMBL14565986 0.77 ABHD6 (0.40) HTTATMJAK3USP30
SCHEMBL14641748 0.76 KDM5A (0.50) NR1H2HTTDDB1CRBNSSTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9186354-B2 Pyrrolidine derived β3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2015-11-17 US disclosed
US-20140315912-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME LLC 2014-10-23 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315912-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 NR1H2 122/4885HTT 4179/4885ATM 3957/4885
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 NR1H2 122/4885HTT 4256/4885ATM 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.